Table 3.
In vitro anti-proliferative activity of the tested compounds 4a–l, 5a–d, and Doxorubicin expressed as IC50 values against prostate cancer (PC3), human colorectal cancer (HCT-116), human hepatocellular carcinoma (HePG-2), human epithelioid carcinoma (HeLa), and MCF7 human cancer cell line.
| Comp. No. |
IC50 (µM) a | ||||
|---|---|---|---|---|---|
| PC3 | HCT-116 | HePG-2 | HeLa | MCF7 | |
| 4a | 63.94 ± 3.8 | 53.17 ± 3.3 | 47.23 ± 3.1 | 28.31 ± 2.0 | 55.34 ± 2.8 |
| 4b | 71.80 ± 4.0 | 77.52 ± 4.1 | 56.34 ± 3.3 | 49.47 ± 3.0 | 68.26 ± 3.4 |
| 4c | 84.52 ± 4.8 | 39.44 ± 2.6 | 78.86 ± 4.1 | 44.69 ± 2.8 | 33.86 ± 2.3 |
| 4d | 78.35 ± 4.5 | 48.30 ± 3.0 | 73.80 ± 3.9 | 54.02 ± 3.2 | 40.52 ± 2.5 |
| 4e | >100 | 92.11 ± 4.9 | >100 | 75.61 ± 3.9 | 88.33 ± 3.9 |
| 4f | 74.67 ± 4.4 | 69.38 ± 3.8 | 58.41 ± 3.5 | 57.26 ± 2.5 | 65.35 ± 3.2 |
| 4g | >100 | 92.11 ± 4.9 | >100 | 75.61 ± 3.9 | 88.33 ± 3.9 |
| 4h | 59.48 ± 3.5 | 35.01 ± 2.7 | 42.74 ± 2.9 | 31.72 ± 2.2 | 29.10 ± 2.1 |
| 4i | 59.48 ± 3.5 | 35.01 ± 2.7 | 42.74 ± 2.9 | 31.72 ± 2.2 | 29.10 ± 2.1 |
| 4j | 95.61 ± 5.1 | 64.07 ± 3.5 | 86.45 ± 4.5 | 61.98 ± 3.5 | 59.87 ± 2.7 |
| 4k | 75.22 ± 4.1 | 61.07 ± 3.4 | 77.40 ± 3.6 | 49.55 ± 3.2 | 29.56 ± 3.6 |
| 4l | 34.60 ± 2.3 | 19.95 ± 1.8 | 17.42 ± 1.4 | 10.96 ± 1.1 | 12.97 ± 1.0 |
| 5a | 52.53 ± 3.3 | 27.49 ± 2.3 | 36.08 ± 2.5 | 24.09 ± 1.8 | 17.80 ± 1.3 |
| 5b | >100 | 89.26 ± 4.6 | 91.78 ± 4.9 | 67.53 ± 3.7 | 79.16 ± 3.6 |
| 5c | 23.92 ± 1.9 | 14.69 ± 1.2 | 11.93 ± 1.0 | 9.50 ± 0.8 | 6.49 ± 0.4 |
| 5d | 38.02 ± 2.5 | 32.81 ± 2.6 | 22.91 ± 1.6 | 18.37 ± 1.4 | 24.33 ± 1.9 |
| Doxorubicin | 8.87 ± 0.6 | 5.23 ± 0.3 | 4.50 ± 0.2 | 5.57 ± 0.4 | 4.17 ± 0.2 |
a IC50 values presented as the mean ± SD of three separate determinations. Significant values (<25 µm) have been bolded for emphasis.